ArticleThe pharmacogenomics journal2005
Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action.
Article in The pharmacogenomics journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Melittin - the main component of bee venom: a promising therapeutic agent for neuroprotection through keap1/Nrf2/HO-1 pathway activation.Chinese medicine · 2024Article
- Identification of pathways associated with chemosensitivity through network embedding.PLoS computational biology · 2019Article
- Article
- Computational discovery of transcription factors associated with drug response.The pharmacogenomics journal · 2016Article
- Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.Antioxidants & redox signaling · 2014Article
- Integrating systems biology sources illuminates drug action.Clinical pharmacology and therapeutics · 2014Article
- Pathway analysis for drug repositioning based on public database mining.Journal of chemical information and modeling · 2014Article
- Systematic analysis of time-series gene expression data on tumor cell-selective apoptotic responses to HDAC inhibitors.Computational and mathematical methods in medicine · 2014Article
- Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens.Chemistry & biology · 2013Article
- Using molecular features of xenobiotics to predict hepatic gene expression response.Journal of chemical information and modeling · 2013Article
- Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening.Journal of ovarian research · 2012Article
- Large-scale elucidation of drug response pathways in humans.Journal of computational biology : a journal of computational molecular cell biology · 2012Article
- Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.PloS one · 2012Article
- The use of genomic information to optimize cancer chemotherapy.Seminars in oncology · 2011Review
- Targeting karyotypic complexity and chromosomal instability of cancer cells.Current drug targets · 2010Review
- Pharmacogenomic discovery using cell-based models.Pharmacological reviews · 2009Review
- Evaluation of molecular descriptors for antitumor drugs with respect to noncovalent binding to DNA and antiproliferative activity.BMC pharmacology · 2009Article
- Gene expression associations with the growth inhibitory effects of small molecules on live cells: specificity of effects and uniformity of mechanisms.Statistical analysis and data mining · 2009Article
- Conditional drug screening shows that mitotic inhibitors induce AKT/PKB-insensitive apoptosis.Journal of chemical biology · 2009Article
- Identifying differential correlation in gene/pathway combinations.BMC bioinformatics · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Novel strategies are proposed to quantitatively analyze and relate biological pathways to drug responses using gene expression and small-molecule growth inhibition data (GI(50)) derived from the National Cancer Institute's 60 cancer cells (NCI(60)). We have annotated groups of drug GI(50) responses with pathways defined by the Kyoto Encyclopedia of Genes and Genomes (KEGG) and BioCarta, and functional categories defined by Gene Ontology (GO), through correlations between pathway gene expression patterns and drug GI(50) profiles. Drug-gene-pathway relationships may then be utilized to find drug targets or target-specific drugs. Significantly correlated pathways and the gene products involved represent interesting targets for further exploration, whereas drugs that are significantly correlated with only certain pathways are more likely to be target specific. Separate pathway clustering finds that pathways engaged in the same biological process tend to have similar drug correlation patterns. The biological and statistical significances of our method are established by comparison to known small-molecule inhibitor-gene target relationships reported in the literature and by standard randomization procedures. The results of our pathway, gene expression and drug-induced growth inhibition associations, can serve as a basis for proposing testable hypotheses about potential anticancer drugs, their targets, and mechanisms of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.